Everolimus attenuates neointimal hyperplasia in cultured human saphenous vein grafts

European Journal of Cardio-thoracic Surgery

Volumn 35, Issue 3, 2009, Pages 515-520

  Semsroth, Severin ^a   Stigler, Robert G ^a   Bernecker, Oliver Y ^a   Ruttmann Ulmer, Elfriede ^a   Troppmair, Jakob ^a   Macfelda, Karin ^b   Bonatti, Johannes O ^a   Laufer, Guenther ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coronary artery bypass grafting; Everolimus; mTOR inhibition; Neointimal hyperplasia; Saphenous vein graft

Indexed keywords

EVEROLIMUS; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6;

ARTERY INTIMA PROLIFERATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; ORGAN CULTURE; PRIORITY JOURNAL; SAPHENOUS VEIN GRAFT;

BLOTTING, WESTERN; CORONARY ARTERY BYPASS; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; KI-67 ANTIGEN; ORGAN CULTURE TECHNIQUES; RIBOSOMAL PROTEIN S6 KINASES; SAPHENOUS VEIN; SIROLIMUS; TUNICA INTIMA; VASCULAR PATENCY;

EID: 60849112550     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.11.035     Document Type: Article

References (22)

1. Fitzgibbon G.M., Kafka H.P., Leach A.J., Keon W.J., Hooper G.D., and Burton J.R. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5065 grafts related to survival and reoperation in 1388 patients during 25 years. J Am Coll Cardiol 28 (1996) 616-626
2. Lytle B.W. Prolonging patency - choosing coronary bypass grafts. N Engl J Med 351 (2004) 2262-2264
3. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 (1998) 916-931
4. Mitra A.K., Gangahar D.M., and Agrawal D.K. Cellular, molecular and immunological mechanisms in the pathophysiology of vein graft intimal hyperplasia. Immunol Cell Biol 84 (2006) 115-124
5. Mourani P.M., Garl P.J., Wenzlau J.M., Carpenter T.C., Stenmark K.R., and Weiser-Evans M.C. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation 109 (2004) 1299-1306
6. Uchida K., Sasahara M., Morigami N., Hazama F., and Kinoshita M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis 124 (1996) 9-23
7. Ishida A., Murray J., Saito Y., Kanthou C., Benzakour O., Shibuya M., and Wijelath E.S. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 188 (2001) 359-368
8. Schmelzle T., and Hall M.N. TOR, a central controller of cell growth. Cell 103 (2000) 253-262
9. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
10. Sakakibara K., Liu B., Hollenbeck S., and Kent K.C. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 288 (2005) H2861-2868
11. Schuler W., Sedrani R., Cottens S., Haberlin B., Schulz M., Schuurman H.J., Zenke G., Zerwes H.G., and Schreier M.H. SDZ RAD a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
12. Porter K.E., Varty K., Jones L., Bell P.R., and London N.J. Human saphenous vein organ culture: a useful model of intimal hyperplasia?. Eur J Vasc Endovasc Surg 11 (1996) 48-58
13. Vezina C., Kudelski A., and Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28 (1975) 721-726
14. Eisenberg M.J., and Konnyu K.J. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis. Am J Cardiol 98 (2006) 375-382
15. Verheye S., Martinet W., Kockx M.M., Knaapen M.W., Salu K., Timmermans J.P., Ellis J.T., Kilpatrick D.L., and De Meyer G.R. Selective clearance of macrophages in atherosclerotic plaques by autophagy. J Am Coll Cardiol 49 (2007) 706-715
16. Martin K.A., Rzucidlo E.M., Merenick B.L., Fingar D.C., Brown D.J., Wagner R.J., and Powell R.J. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 286 (2004) C507-C517
17. Schachner T., Oberhuber A., Zou Y., Tzankov A., Ott H., Laufer G., and Bonatti J. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardiothorac Surg 27 (2005) 302-306
18. Kawatsu S., Oda K., Saiki Y., Tabata Y., and Tabayashi K. External application of rapamycin-eluting film at anastomotic sites inhibits neointimal hyperplasia in a canine model. Ann Thorac Surg 84 (2007) 560-567 discussion 567
19. Qi X.R., Yan Y., Ma X.D., Li T.Y., Nie X.Y., and Yang B.B. Development of a local vasodilator delivery system using fibrin glue to prevent arterial graft from spasm. J Biomed Mater Res A 82 (2007) 139-144
20. Hinokiyama K., Valen G., Tokuno S., Vedin J.B., and Vaage J. Vein graft harvesting induces inflammation and impairs vessel reactivity. Ann Thorac Surg 82 (2006) 1458-1464
21. Cortot A., Armand J.P., and Soria J.C. PI3K-AKT-mTOR pathway inhibitors. Bull Cancer 93 (2006) 19-26
22. Alexander J.H., Hafley G., Harrington R.A., Peterson E.D., Ferguson Jr. T.B., Lorenz T.J., Goyal A., Gibson M., Mack M.J., Gennevois D., Califf R.M., and Kouchoukos N.T. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 294 (2005) 2446-2454